ALEC: the cash flow

MyFinsight

For the year ending 2025-12-31, ALEC had $32,781K increase in cash & cash equivalents over the period. -$184,072K in free cash flow.

Cash Flow	2025-12-31
Net loss	-142,929
Depreciation and amortization	5,718
Stock-based compensation	26,658
Amortization of premiums and accretion of discounts on marketable securities	6,579
Amortization of right-of-use assets	3,943
Amortization of debt discount and debt issuance costs	293
Impairment loss of right-of-use assets and leasehold improvements	2,922
Prepaid expenses and other current assets	-992
Other assets	-4,158
Accounts payable	-524
Accrued liabilities and accrued clinical supply costs	-12,904
Payable to collaboration partner	11,375
Deferred revenue	-21,045
Refund liability to collaboration partner	50,027
Lease liabilities	-6,585
Other long-term liabilities	503
Net cash used in operating activities	-184,031
Purchase of property and equipment	41
Purchase of marketable securities	271,879
Maturities of marketable securities	465,536
Sale of marketable securities	2,981
Net cash provided by investing activities	196,597
Proceeds from the exercise of options to purchase common stock	15
Proceeds from issuance of stock from employee stock purchase plan	217
Proceeds from issuance of common stock, net of issuance costs	19,983
Proceeds from debt financing, net of discount and issuance costs	0
Net cash provided by financing activities	20,215
Net increase (decrease) in cash, cash equivalents, and restricted cash	32,781
Cash, cash equivalents, and restricted cash at beginning of period	34,867
Cash, cash equivalents, and restricted cash at end of period	67,648

Unit: Thousand (K) dollars (except for numbers of shares and EPS).